Subjects who are on systemic corticosteroids (intravenous (IV) or oral steroids, excluding inhaled, topical or ophthalmic corticosteroids), or anti-epileptic drugs for treated brain metastasis
No chronic (>=  month) use of oral steroids at the time of study enrollment; inhaled or topical steroids are acceptable
Corticosteroids or any other immunosuppressive therapy - weeks NOTE: Use of inhaled or topical steroids is not an exclusion
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary; topical or inhaled steroids are allowed
Have chronic daily treatment with corticosteroids, excluding inhaled or topical steroids.
Concurrent use of high dose of systemic steroids. The use of inhaled, topical and ophthalmic steroids is allowed.
Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; Note: Patients who are currently using inhaled, intranasal, ocular, topical or other non-oral or non-IV steroids are not necessarily excluded from the study but need to be discussed with the study chair
No escalation of systemic immunosuppression in terms of increase of corticosteroids or addition of new agent / modality within  weeks of randomization. (Note that increasing calcineurin inhibitors or sirolimus to achieve therapeutic trough levels is allowed.) Topical skin and topical gastrointestinal steroids are allowed.
Patients with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV), or an autoimmune disorder requiring systemic cytotoxic or immunosuppressive therapy are not eligible; Note: patients that are currently using inhaled, intranasal, ocular, topical or other non-oral or non-intravenous (IV) steroids are not necessarily excluded from the study but need to be discussed with the study chair
Chronic, systemic treatment with immunosuppressive agents; patients who require a stable dose of corticosteroids for control of cerebral edema are eligible; topical or inhaled steroids are also allowed
Inhaled, intranasal, intraarticular, and topical steroids are permitted.
Use of prednisone or equivalent systemic corticosteroid within  weeks of treatment; use of inhaled, intranasal, intra-articular, and topical steroids is allowed; oral or IV steroids to prevent or treat IV contrast reactions are allowed
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids or steroids given for the purpose of adrenal replacement given at physiologic doses
Concomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (other than at the proposed vaccination sites) or inhalational steroids are permitted
Current treatment with systemic steroid therapy (inhaled/topical steroids are acceptable); systemic corticosteroids must be discontinued for at least  weeks prior to first treatment with ipilimumab
Subjects receiving systemic (oral or parenteral) corticosteroid therapy within  days of first dose of study drug or a requirement for chronic systemic immunosuppressive therapy for any reason. Topical or inhaled steroids are allowed.
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Requirement for systemic corticosteroids unless used for adrenal replacement, acute therapy for asthma or bronchitis exacerbation (=<  weeks), or premedication for contrast allergy\r\n* Topical, intranasal, or inhaled steroids are not excluded
Subjects receiving topical steroids or other topical treatments for CTCL within  weeks.
Treatment with any of the following medications or interventions within  days of registration:\r\n* Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable\r\n* Ketoconazole\r\n* High dose calcitriol [,(OH)VitD] (i.e., > . ug/week)\r\n* Any other systemic therapy for prostate cancer (except for medical castration)
Patients receiving concomitant immunosuppressive agents or chronic corticosteroid use, except those on steroid to control brain metastases, those on topical or inhaled steroids, or steroids given via local injection
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
Ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last  weeks before enrollment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)
Patients requiring steroids or other immunosuppressive therapy; low-dose or topical steroids are allowable if being used as replacement therapy
Patients are excluded if they have any concurrent medical condition requiring the use of systemic steroids (the use of inhaled or topical steroids is permitted).
Anticancer topical therapy, including therapeutic doses of steroids, within  weeks prior to initiating study treatment; Note: Topical steroids at doses intended for symptom management are permitted prior to study enrollment and may continue during study treatment
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Systemic steroids should be stopped  weeks before the start of treatment; topical and inhaled steroids are allowed
Current systemic steroid therapy (inhaled or topical steroids are also not allowed)
Active immunosuppressive or cytotoxic therapy (excluding topical steroids) for any other condition.
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses or isolated use of steroids as premedication for medical procedures to minimize allergic reaction [e.g. computed tomography (CT) scan dye] are allowed)
Patients must not receive concurrent systemic or topical steroids or other skin directed therapy while on study
Patients receiving systemic steroid therapy for a chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's Disease, etc.). Topical steroids are also excluded. Nasal and inhaled steroids are permitted.
Have a diagnosis of immunodeficiency, either primary or acquired, or treatment with systemic steroids or any other form of immunosuppressive therapy within  days prior to CD. Exception: inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease as well as a one-time dose of immunosuppressive agents used prophylactically for contrast allergies
No systemic oral steroids administered within  days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes
Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
Subjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.
Patients who require pharmacologic doses of corticosteroids; replacement, topical, ophthalmologic and inhalational steroids are permitted.
Systemic corticosteroid use within past  days; use of inhaled, intranasal, and topical steroids is acceptable
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Chronic treatment with systemic steroids or other immunosuppressive agents; Note: topical or inhaled steroids are allowed
No systemic oral steroids administered within  days prior to initiating treatment on protocol; topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes
Systemic immunosuppressive medications such as steroids; the following steroid formulations are permitted: intranasal, intra-articular, and inhaled steroids
Active immunosuppressive therapy (excluding topical steroids) for any other condition.
Concurrent oral corticosteroid use aside from adrenal replacement, or use of other immunosuppressive agents (ex: infliximab); topical or inhaled steroids will be allowed
Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
Treatment with oral/systemic corticosteroids; NOTE: with the exception of topical or inhaled steroids
Concomitant treatment with corticosteroids greater than physiologic doses (used in the management of cancer or non-cancer-related illnesses); topical (if not including the proposed vaccination sites) or inhalational steroids are allowed
Participants that have been receiving the following medications or treatments within the  weeks ( days) prior to consenting:\r\n* Corticosteroids, administered parenterally, orally, or inhaled (inhaled steroids, such as: Advair, Flovent, Azmacort)\r\n* Topical corticosteroids are acceptable
Current treatment with systemic steroid therapy (inhaled/topical steroids are acceptable); systemic corticosteroids must be discontinued for at least  days prior to first CYT injection
Concurrent use of systemic corticosteroids (nasal corticosteroids, inhaled steroids, adrenal replacement steroids, and topical steroids are allowed)
Ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporine, or with a history of chronic use of any such medication within the last  weeks before enrolment; patients are excluded if they have any concurrent medical condition that requires the use of systemic steroids (the use of inhaled or topical steroids is permitted)
Treatment with any of the following medications or interventions within  days of registration:\r\n* Systematic corticosteroids; use of inhaled, intranasal, and topical steroids is acceptable\r\n* Any other systemic therapy for prostate cancer (except for medical castration)
Patients who require systemic corticosteroid or other immunosuppressive therapy for GVHD; immunosuppressive therapy must be stopped at least  days prior to protocol course  day  (CD); steroids for physiologic replacement, for ALL maintenance or topical agents and/or inhaled corticosteroids are permitted
Patients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agents
Patients are ineligible if they have any concurrent medical condition requiring the use of systemic steroids; (use of inhaled or topical steroids is acceptable)
Use of systemic steroid therapy within  days of study screening; patients on inhaled or topical steroids are eligible
Inhaled steroids are permitted
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last  weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
Medical conditions (aside from newly-diagnosed brain metastases) for which the chronic use of corticosteroids or other immunosuppressive medications are indicated; Note: inhaled and topical steroids are permitted
Systemic corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism. Patients receiving inhaled or topical corticosteroids may participate (if therapy is <  days and is limited to systemic steroids as antiemetics).
Systemic steroids should be stopped  weeks before the start of treatment; topical and inhaled steroids are allowed
Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within  months prior to enrolment.
Immunosuppressive therapy (excluding topical steroids) for any other condition =<  weeks prior to registration
Subjects taking systemic (parentally or orally) corticosteroid therapy for any reason, including replacement therapy for hypoadrenalism, are not eligible. Topical steroids are acceptable as are intranasal steroids.
Any prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a total dose of  mg or equivalent within  days prior to the first dose of study treatment). Use of topical or inhaled steroids is acceptable
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
No systemic corticosteroids or immunosuppressive drugs (topical acceptable); replacement steroids for adrenal insufficiency are not excluded
Current treatment with systemic steroid therapy (inhaled/topical steroids are acceptable). Systemic corticosteroids must be discontinued for at least  weeks prior to first treatment.
Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs  days before initiation of study treatment. Steroids with no or minimal systemic effect (topical, inhalation) are allowed. Note: Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated ? days before first dose of AGEN. Note: Use of inhaled or topical corticosteroid is permitted. Note: Steroid pre-medication for radiographic imaging for dye allergies is permitted.
Subjects who have used systemic corticosteroids or other immunosuppressants for any condition within  days of randomization. Inhaled or topical steroids are permitted.
No concurrent use of systemic steroids, except for local (topical, nasal, or inhaled) steroid use (replacement doses of steroids allowed)
Subjects who require pharmacologic doses of corticosteroids; replacement doses, topical, ophthalmologic, and inhalational steroids are permitted
A requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents; topical, nasal, and inhaled steroids are permitted
A requirement for daily systemic corticosteroids for any reason or a requirement for other immunosuppressive or immunomodulatory agents; topical, nasal, and inhaled steroids are permitted
Treatment with oral/systemic corticosteroids =<  days prior to registration, with the exception of topical or inhaled steroids or steroids given for the purpose of antiemetics during chemotherapy
Immunosuppressive or systemic steroids medication within  days before the first dose of KTN (inhaled and topical corticosteroids are permitted).
Use of immunosuppressive medication within  days before the first dose of mogamulizumab. Note: Inhaled, intranasal, intra-articular, or topical corticosteroids are allowed. Non-immunosuppresive doses of systemic steroids for adrenal replacement or for contrast allergy are allowed;;
Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
Has any pre-existing medical condition requiring systemic chronic steroid or immunosuppressive therapy a) Inhaled corticosteroids for COPD or topical steroids are allowed
Any concurrent medical condition requiring the use of systemic steroids is not permitted (the use of inhaled or topic steroids is permitted)
Use of oral or intravenous corticosteroids or other immunosuppressive medications such as cyclosporine or azathioprine; subjects must not have received any systemic immunosuppressive drug such as corticosteroids for at least  weeks prior to study entry; maintenance inhaled corticosteroids for controlled asthma or chronic obstructive pulmonary disease (COPD) or maintenance systemic steroids to correct autoimmune endocrinopathy due to prior ipilimumab treatment is allowed as is the use of topical steroids and anti-inflammatory eye drops
Inhaled, intranasal, intraarticular and topical steroids are permitted
Use of corticosteroids, thalidomide, bortezomib, or cytotoxic chemotherapy within  weeks of the first dose of elotuzumab except for steroids with little or no systemic absorption (ie, topical or inhaled steroids).
Concurrent treatment with systemic corticosteroids; local (inhaled or topical) steroids are permitted
Corticosteroids or any other immunosuppressive therapy within  weeks. Use of inhaled or topical cutaneous steroids is permitted.
Patients must not use topical steroids (e.g., hydrocortisone). Topical over-the-counter antibiotics (e.g., Neosporin) and skin protectants (e.g., Vaseline, Aquaphor) for local skin fissures on hands and feet.\r\n* Note: Patients are allowed to use topical medications on other body parts, besides the hands and feet, but must use qtips or gloves for application.
Patient has received systemic corticosteroids or sedative antihistamines (dimenhydrinate, diphenhydramine, etc.) within  hours of day  of the study except as premedication for chemotherapy (e.g., taxanes); subjects who are receiving inhaled steroids for respiratory conditions or topical steroids for skin disorders can be enrolled
Patients on chronic steroid therapy or other immunosuppressive therapy except for topical or inhaled steroids known to have low systemic absorption
Recent (within  weeks of screening) or concomitant long term treatment with systemic steroids, immunosuppressive/immunomodulating drugs (e.g. cyclosporine, corticosteroids)\r\n* Intranasal, inhaled and/or topical steroids are permissible
Therapeutic doses of corticosteroids within  days of leukapheresis or  hours prior to JCAR administration. Physiologic replacement, topical, inhaled, and intranasal steroids are permitted.
Clinical requirement for systemic corticosteroids for control of cerebral edema or for enzyme-inducing anticonvulsants; (inhaled steroids and systemic steroids for chronic obstructive pulmonary disease [COPD] are permitted)